# ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct05932615` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05932615](<https://clinicaltrials.gov/study/NCT05932615>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05932615

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT05932615. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT05932615, source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)
- Started: 2024-03-15 (actual) (ClinicalTrials.gov record NCT05932615, source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT05932615, source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)
- Completion: 2036-04 (anticipated) (ClinicalTrials.gov record NCT05932615, source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Canada; Denmark; France; Germany; Israel; Italy; Netherlands; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05932615, source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05932615-2026-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
- Acronym: ENVISION
- Condition: Aortic Valve Stenosis
- Condition: Heart Valve Diseases
- Condition: Aortic Valve Disease
- Condition: Heart Disease Structural Disorder
- Intervention (Device): Navitor Transcatheter Aortic Valve Implantation (TAVI) System
- Intervention (Device): Any Commercially Available Transcatheter Aortic Valve (CAV) System
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: a335f3d3c0e8cf3526710354d6d1234c7975735305bf680bbfda7a7533d32ab5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
